OCM™

(Omeza Complete Matrix – A2014)

Wound Care Matrix

First-of-its kind drug device

Multimodal Therapy for all Wound Phases

OCM™ is a first-in-class, HCP-administered, drug device delivering complete and personalized therapy to address all phases of wound healing:

  • An illustration of biolfilmReduce biofilm impact
  • Illustration of inflammation reductionDecrease inflammation
  • Illustration of tissue regeratingIncrease proliferation
  • Illustration of a wall being builtSupport remodeling

How Does OCM™ Work?

An illustration of a yellow, malleable material on a wound

OCM™ is a malleable solid to fit any wound shape

A First of its Kind Drug-Device

  • First in class formulation with multi-modal mechanisms of action
  • Treats most types of chronic wounds and patients

OCM™ is Created Through a Proprietary Process

  • An amorphous solid covers the wound bed (including tunnels)
  • This malleable sheet provides support for comprehensive healing

Contains

Cold Water Fish Peptides

  • Building blocks for tissue regeneration
  • Cell signaling molecule

Pharmaceutical-Grade Components

  • Natural, non-cytotoxic components known to be antimicrobial
  • Reduces biofilm impact
  • Reduces inflammation
  • Increases proliferation
  • Supports remodeling

OCM™ Considerations for Use

Dosage and Handling

  • OCM™ is HCP administered using aseptic techniques 
  • Each OCM™ device covers approximately 16 cm sq or 4 cm x 4 cm area 
  • Apply maximum 2 OCM™ devices per day; maximum 4 OCM™ devices per week 
  • Reapplication determined by HCP 
  • Reapply when OCM™ has been naturally incorporated into the wound bed 

Other Considerations

  • Proper wound bed preparation and dressings are necessary for optimal results 
  • After application, cover with non-stick dressing and secure with steri-strips 
  • Use offloading and other wound care procedures as appropriate 
  • OCM™ can be used with NPWT and HBOT 

Indications

Indications Include

  • Partial and full-thickness wounds
  • Pressure ulcers
  • Diabetic ulcers
  • Chronic vascular ulcers
  • Venous ulcers
  • Dehisced wounds

Contradictions

  • Sensitivity to fish or cod liver oil.
  • Third-degree burns.

Case Studies

Clinical Evidence Shows 60% PAR* in 4 Weeks

* Percentage Area Reduction

Diabetic Foot Ulcer With Charcot Deformity

Diabetic foot ulcer with Charcot deformity - Week 1
Week 1
Diabetic foot ulcer with Charcot deformity - Week 3
Week 3
Diabetic foot ulcer with Charcot deformity - Week 9
Week 9

Wound history & prior therapies: 4 months nonhealing. Collagen powder & off-loading boot.
Omeza: Closed in 9 weeks

Venous Leg Ulcer

Venous leg ulcer - Initial wound
Initial Wound
Venous leg ulcer - Week 2
Week 2
Venous leg ulcer - Week 5
Week 5

Wound history & prior therapies: 7 months nonhealing. Silver alginate & amnion products.
Omeza: Closed in 5 weeks

Tunneling Abdominal Wound

Tunneling abdominal wound - Week 1
Week 1
Tunneling abdominal wound - Week 3
Week 3
Tunneling abdominal wound - Week 7
Week 7

Wound history & prior therapies: Over 2 years old. Standard of care in skilled nursing facility.
Omeza: Closed in 7 weeks

Venous Leg Ulcer

Venous leg ulcer - Week 1
Week 1
Venous leg ulcer - Week 8
Week 8
Venous leg ulcer - Week 11
Week 11

Wound history & prior therapies: 5 months nonhealing. Compression, unna boots, fish skin graft.
Omeza: Closed in 11 weeks

OCM™ Wound Care Matrix by Omeza

Ordering Information

HCPCS Code

OCM™ CMS Code: A2014

OCM packaging

* Case studies shown have utilized OCM, Omeza Lidocaine Lavage, and Omeza Skin Protectant.

* N=84 as of 2023

See IFU for full indications and precautions; Omeza, LLC data on file

Resources: Data on file OCM MOA video OCM 510(k) application

OCM™ Wound Care Matrix is manufacured by Omeza, LLC.

Request more information or place an order.

Contact Us